Tumor Biology

, Volume 36, Issue 6, pp 4417–4426 | Cite as

Protein kinase D2 silencing reduced motility of doxorubicin-resistant MCF7 cells

  • Aktan Alpsoy
  • Ufuk GündüzEmail author
Research Article


Success of chemotherapy is generally impaired by multidrug resistance, intrinsic resistance, or acquired resistance to functionally and structurally irrelevant drugs. Multidrug resistance emerges via distinct mechanisms: increased drug export, decreased drug internalization, dysfunctional apoptotic machinery, increased DNA damage repair, altered cell cycle regulation, and increased drug detoxification. Several reports demonstrated that multidrug resistance is a multifaceted problem such that multidrug resistance correlates with increased aggressiveness and metastatic potential. Here, we tested the involvement of protein kinase D2, a serine/threonine kinase that was previously implicated in proliferation, drug resistance, and motility in doxorubicin-resistant MCF7 (MCF7/DOX) cell line, which served as an in vitro model for drug resistance and invasiveness. We showed that basal level activity of protein kinase D2 (PKD2) was higher in MCF7/DOX cells than parental MCF7 cells. To elucidate the roles of PKD2 MCF7/DOX, PKD2 expression was reduced via small interfering RNA (siRNA)-mediated knockdown. Results showed that acquired resistance of MCF7/DOX to doxorubicin was not affected by PKD2 silencing, while motility of MCF7/DOX cells was reduced. The results implied that PKD2 silencing might inhibit migration of MCF7/DOX cells without affecting chemoresistance significantly.


Multidrug resistance Breast cancer Migration Protein kinase D2 



We thank Assoc. Dr. Özlem Darcansoy İşeri and Assoc. Dr. Meltem Demirel Kars for developing MCF7/DOX subline and Çağrı Urfalı Mamatoğlu for critical reading. We greatly acknowledged Soner Yildiz and Assoc. Prof. Dr. Mayda Gürsel for their contributions in flow cytometry. This work was supported by TUBITAK 1002 Short Term R&D Funding Program (Grant ID: 112T714) and METU Research Fund (Grant ID: BAP-07-02-2012-101-22).

Conflicts of interest


Supplementary material

13277_2015_3081_Fig8_ESM.gif (203 kb)
Supplementary Fig. 1

PKD2 knockdown increases the migration of parental MCF7 cell line. MCF7 cells were transfected for 72 h. Cells are collected and seeded at a density of 100 000 cells in 200 μl 0.5 % FBS medium per transwell insert. Cells are allowed to migrate toward 10 % FBS medium for 48 h. (A) RT-qPCR analysis demonstrated that PKD2 levels remained downregulated at fifth day. (B) Migrating cells on transwell membrane were fixed, stained and counted. Representative images of membranes were taken at 20X magnification. (GIF 202 kb)

13277_2015_3081_MOESM1_ESM.tif (912 kb)
High-resolution image (TIFF 911 kb)


  1. 1.
    Choi C-H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:30.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gillet J, Gottesman MM. In: Zhou J, editor. Multi-drug resistance in cancer. Totowa: Humana; 2010. p. 596.Google Scholar
  3. 3.
    Baguley BC. Multidrug resistance in cancer. In: Zhou J, editor. Multi-drug resistance in cancer. Humana; 2010. page 4–6.Google Scholar
  4. 4.
    Lage H. Review an overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65:3145–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother. 2011;65:40–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417:679–85. Elsevier Inc.CrossRefPubMedGoogle Scholar
  7. 7.
    Saxena M, Stephens MA, Pathak H, Rangarajan A, Nature Publishing Group. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lamouille S, Xu J, Derynck R, Nature Publishing Group. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Li Q-Q, Xu J-D, Wang W-J, Cao X-X, Chen Q, Tang F, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009;15:2657–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Rozengurt E, Rey O, Waldron RT. Protein kinase D signaling. J Biol Chem. 2005;280:13205–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Storz P. In: Chatterjee M, Kashfi K, editors. Cell signaling & molecular targets in cancer. New York: Springer; 2012. p. 245–71.CrossRefGoogle Scholar
  12. 12.
    Jackson LN, Li J, Chen LA, Townsend CM, Evers BM. Overexpression of wild-type PKD2 leads to increased proliferation and invasion of BON endocrine cells. Biochem Biophys Res Commun. 2006;348:945–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Huck B, Duss S, Hausser A, Olayioye MA. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem. 2014;289:3138–47.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu P, Scharenberg AM, Cantrell DA, Matthews SA. Protein kinase D enzymes are dispensable for proliferation, survival and antigen receptor-regulated NFkappaB activity in vertebrate B-cells. FEBS Lett. 2007;581:1377–82.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hao Q, Wang L, Zhao ZJ, Tang H. Identification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesis. J Biol Chem. 2009;284:799–806.CrossRefPubMedGoogle Scholar
  16. 16.
    Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol. 2010;10:5.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chen J, Deng F, Singh SV, Wang QJ. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008;68:3844–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Hao Q, McKenzie R, Gan H, Tang H. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res. 2013;33:393–9.PubMedGoogle Scholar
  19. 19.
    Karam M, Legay C, Auclair C, Ricort J-M. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp Cell Res. 2012;318:558–69. Elsevier Inc.CrossRefPubMedGoogle Scholar
  20. 20.
    Storz P, Toker A. Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway. EMBO J. 2003;22:109–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fu Y, Rubin CS. Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology. EMBO Rep. 2011;12:785–96.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Armacki M, Joodi G, Nimmagadda SC, de Kimpe L, Pusapati GV, Vandoninck S, et al. A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis. Oncogene. 2014;33:1167–80. Macmillan Publishers Limited.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen J, Lu L, Feng Y, Wang H, Dai L, Li Y, et al. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 2011;300:48–56. Elsevier Ireland Ltd.CrossRefPubMedGoogle Scholar
  24. 24.
    Xiao M, Liu Y, Zou F. Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. Exp Cell Res. 2012;318:43–52. Elsevier Inc.CrossRefPubMedGoogle Scholar
  25. 25.
    Eiseler T, Döppler H, Yan IK, Goodison S, Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res. 2009;11:R13.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA, Hausser A. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 2009;69:5634–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Döppler H, Bastea LI, Borges S, Spratley SJ, Pearce SE, Storz P. Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration. PLoS One. 2014;9:e98090.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bernhart E, Damm S, Wintersperger A, DeVaney T, Zimmer A, Raynham T, et al. Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp Cell Res. 2013;319:2037–48. Elsevier.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Borges S, Storz P. Protein kinase D isoforms: new targets for therapy in invasive breast cancers? Expert Rev Anticancer Ther. 2013;13:895–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Kars MD, Iseri OD, Gündüz U, Ural AU, Arpaci F, Molnár J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006;26:4559–68.PubMedGoogle Scholar
  31. 31.
    Tezcan O, Gündüz U. Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells. Biomed Pharmacother. 2014;68:357–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010;38:D792–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Häcker S, et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene. 2012;31:4677–88.CrossRefPubMedGoogle Scholar
  34. 34.
    Kaplan E, Gündüz U. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed Pharmacother. 2012;66:29–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Sturany S, Van Lint J, Muller F, Wilda M, Hameister H, Hocker M, et al. Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem. 2001;276:3310–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Dönmez Y, Gündüz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother. 2011;65:85–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22:7496–511.CrossRefPubMedGoogle Scholar
  38. 38.
    Du C, Zhang C, Hassan S, Biswas MHU, Balaji KC. Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res. 2010;70:7810–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Jaggi M, Rao PS, Smith DJ, Wheelock MJ, Johnson KR, Hemstreet GP, et al. E-cadherin phosphorylation by protein kinase D1/protein kinase C μ is associated with altered cellular aggregation and motility in prostate cancer is associated with altered cellular aggregation and motility in prostate. Cancer. 2005;483–92.Google Scholar
  40. 40.
    Wille C, Köhler C, Armacki M, Jamali A, Gössele U, Pfizenmaier K, et al. Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Mol Biol Cell. 2014;25:324–36.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Rogers KMA, Thomas M, Galligan L, Wilson TR, Allen WL, Sakai H, et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther. 2007;6:1544–51.CrossRefPubMedGoogle Scholar
  43. 43.
    Trauzold A, Schmiedel S, Sipos B, Wermann H, Westphal S, Röder C, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene. 2003;22:8939–47.CrossRefPubMedGoogle Scholar
  44. 44.
    Armacki M. Identification and characterization of PKD2 substrates -CIB1a as a substrate for PKD2 [dissertation]. Ulm: Universitätsklinikum Ulm; 2010.Google Scholar
  45. 45.
    Christoforides C, Rainero E, Brown KK, Norman JC, Toker A. PKD controls αvβ3 integrin recycling and tumor cell invasive migration through its substrate Rabaptin-5. Dev Cell. 2012;23:560–72. Elsevier Inc.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ziegler S, Eiseler T, Scholz R-P, Beck A, Link G, Hausser A. A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Mol Biol Cell. 2011;22:570–80.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Biological SciencesMiddle East Technical UniversityAnkaraTurkey

Personalised recommendations